Daiichi Sankyo and Interna partner for MNM-targeted delivery solutions
Pharmaceutical Business Review
The agreement involves Daiichi Sankyo Research Institute Boston and aims to assess the use of Interna's MNM technology as a delivery enhancer for therapeutic modalities.
pharminent
April 17, 2026 (Last updated: April 17, 2026)
Pharmaceutical Business Review
The agreement involves Daiichi Sankyo Research Institute Boston and aims to assess the use of Interna’s MNM technology as a delivery enhancer for therapeutic modalities.